Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy

Authors:

Abstract
The role that the bone marrow microenvironment plays in differentiation, migration, proliferation, survival and drug resistance of malignant plasma cells has attracted significant attention in the attempt to identify new druggable targets in multiple myeloma (MM).[1][1] Heparanase is an endo-β-d-